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Abstract 
Introduction: Preimplantation genetic diagnosis and screening (PGD/PGS) has been 
applied clinically for >25 years however inherent drawbacks include the necessity to 
tailor each case to the trait in question, and that technology to detect monogenic and 
chromosomal disorders respectively is fundamentally different.  
Areas Covered: The area of preimplantation genetics has evolved over the last 25 
years, adapting to changes in technology and the need for more efficient, 
streamlined diagnoses. Karyomapping allows the determination of inheritance from 
the (grand)parental haplobocks through assembly of inherited chromosomal 
segments. The output displays homologous chromosomes, crossovers and the 
genetic status of the embryos by linkage comparison, as well as chromosomal 
disorders. It also allows for determination of heterozygous SNP calls, avoiding the 
risks of allele dropout, a common problem with other PGD techniques. Manuscripts 
documenting the evolution of preimplantation genetics, especially those investigating 
technologies that would simultaneously detect monogenic and chromosomal 
disorders, were selected for review. 
Expert Commentary: Karyomapping is currently available for detection of single gene 
disorders; ~1000 clinics worldwide offer it (via ~20 diagnostic laboratories) and 
~2500 cases have been performed. Due an inability to detect post-zygotic trisomy 
reliably however and confounding problems of embryo mosaicism, karyomapping 
has yet to be applied clinically for detection of chromosome disorders. 
Keywords: PGT, Karyomapping, PGD, PGS, IVF 
 
1. Introduction  
1.1 The need for karyomapping 
Over the last 25 years or more, one of the main advances in assisted reproduction 
technology (ART) has been the development of preimplantation genetics. 
Preimplantation genetics refers to the genetic profiling of oocytes or embryos before 
transfer into the uterus, through use of cytogenetic and/or molecular biology 
techniques [1]. These technologies collectively allow for the diagnosis of monogenic 
defects, chromosome copy number abnormalities and/or unbalanced segmental 
chromosomal rearrangements in a bid to eliminate or at least reduce the risk of 
affected live-born individuals, implantation failure and pregnancy loss [2-4]. The 
technique was first introduced in the late 1960s as proof of principle allowing the 
successful birth of selectively sexed rabbits [5]. However, it wasn’t until 1990 that this 
technology was successfully applied clinically with the use of sex selection for two 
couples at risk of transmitting X-linked disorders Adrenoleukodystrophy (ALD) and X-
linked mental retardation [6]. At the same time, Verlinsky and colleagues described a 
protocol for polar body testing for patients at risk of transmitting PI type ZZ alpha-1-
antitrypsin deficiency (AATD). Although no pregnancies were established, this study 
showed that proof of principle for polar body testing for monogenic disease [7]. Later 
Handyside and colleagues reported the first live birth following PGD for a single gene 
disorder, by screening for the deltaF508 mutation in the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene [8]. 
Typically, clinical use of preimplantation genetics is divided into preimplantation 
screening (PGS) and preimplantation genetic diagnosis (PGD). PGS (or PGD-A) 
refers to non-targeted technologies that detect chromosome abnormalities 
(principally aneuploidy), whereas PGD generally pertains to the detection of single 
gene disorders, translocations and Human Leukocyte Antigen (HLA) matching for 
immunological compatibility testing [9-11]. This technology was applied clinically for 
the first time for the treatment of Fanconi anaemia (FA) by HLA matching [12] and 
has since been shown in many clinical studies that PGD in combination with HLA 
typing is an effective therapeutic tool for treatment of an affected sibling [13-16]. 
PGD is theoretically applicable to any monogenic disorder, but the most common are 
cystic fibrosis, beta-thalassemia, myotonic dystrophy, Huntington’s disease and 
fragile X syndrome [11, 17]. Several studies have reported the combining the 
detection of single gene disorders and chromosomal abnormalities in IVF samples 
[18-21]. Rechitsky and colleagues first described the simultaneous detection of 
chromosome copy number and cystic fibrosis [22], however the ultimate goal of a 
single test that would simultaneously detect monogenic and chromosomal disorders 
had been a key aim of preimplantation genetics for many years [23, 24]. 
Karyomapping has provided this opportunity.  
 
1.2 Technical issues associated with PGD/PGS 
The development of polymerase chain reaction (PCR) and the increase in its 
sensitivity to be applicable to single cells paved the way for interrogation of target 
genomic sequences that code for known genetic defects [25, 26]. DNA is released 
from a lysed cell that has been collected following embryo biopsy on day three or 
day five of development and the relevant locus is amplified to a detectable level. 
Traditionally, the amplified DNA is then analysed for the presence or absence of the 
mutation [27]. This process has a series of technical challenges as the small amount 
of DNA (5–10pg) found in a single cell increases the risk of DNA contamination, 
amplification failure [25]. A major drawback that imposed limitations on single cell 
PGD is allele dropout (ADO), which can have a significant impact on diagnostic 
accuracy. ADO is the failure to amplify one of two alleles at a heterozygous locus, 
thereby making what should be a heterozygous call appear homozygous. The issue 
of ADO was also highlighted by Rechitsky et al. who investigated the incidence of 
ADO in polar body and blastomere testing. This study emphasised the importance of 
determining ADO frequency for all loci to avoid cases of misdiagnosis [28].  
ADO is a particular problem single cell PCR due to the low amount of starting DNA 
[27]. In the original clinical PGD study [6] PCR was used to perform sex 
determination through the amplification of repetitive Y-specific sequences that 
provided a larger original target sequence on which to work. This technique was 
however found to be susceptible to amplification failure and contamination, which 
can lead to misdiagnosis. Even with newer approaches to detecting sex 
chromosome sequences (e.g. [29-32]) similar problems of misdiagnosis remained. 
Greater specificity was achieved through nested PCR [8], which, in part, allowed for 
the detection of sequence-specific changes. Early examples included detecting the 
causative mutations associated with cystic fibrosis and Alpha-1 Antitrypsin (A1AT) 
deficiency [8]. This heralded an era of mutation detection in PGD (e.g. [33-36]).  
 
1.3 The utility of polymorphic linked markers to increase diagnostic accuracy 
Data gleaned from the sequencing of the human genome [37-40] identified 
polymorphic markers across the genome that could be used in a multiplex PCR 
protocol for single cell diagnosis [24]. Targeted haplotyping of the embryo through 
multiplex PCR of short tandem repeat (STR) markers provided increased accuracy 
of testing and minimized potential errors caused by undetected allele dropout (ADO) 
or contamination [24, 41]. This is due to the fact that the markers close to the 
affected gene, when compared through linkage analysis by establishing the variant 
present in the affected parental DNA, provided verification of the results received 
from the direct mutation detection [24]. Such analyses were however limited to the 
number of PCR experiments that could reasonably be performed and genome-wide 
analyses e.g. with SNP microarrays (see later) greatly increased the utility of linkage-
based analyses for preimplantation genetics.  
Furthermore, technical advances in the amplification of whole genomic DNA (see 
later), as well as the development of fluorescent PCR, allowed an increase in the 
number of additional informative linked markers, which subsequently increased the 
accuracy of the test [17, 42, 43]. Harper and colleagues reported a misdiagnosis rate 
of 10/3727 (0.27%) between 1997 and 2007 after embryo transfer that was then 
determined to be from contamination or allele dropout [27, 44]. One of the main uses 
of multiplex strategies in part using polymorphic markers was in order to provide 
analysis of the Human Leukocyte Antigen (HLA) region in order to match embryos to 
affected children [20, 45]. Thus, the method of using closely linked STR markers 
flanking the gene of interest became established as the gold standard method for 
PGD at the turn of the century in comparison to other technologies [23, 46]. An 
underlying problem of the above approach is that the development of a robust, 
accurate multiplex PCR test that is patient, disease or locus specific, is labour 
intensive and time consuming. Therefore, the couple typically had to wait for a 
significant amount of time, sometimes several months, before a treatment cycle 
could take place. This delay can cause much stress to them and possibly a reduction 
in fertility potential, especially couples with advanced maternal age, as they wait for 
test completion. Further to this, this targeted approach provided little information 
about chromosome copy number, which is known to be a major contributing factor of 
implantation failure, recurrent miscarriage and mental retardation [24, 47-50]. 
Karyomapping was developed to circumvent these problems.  
 
1.4 Detection of chromosome copy number 
The first recorded case of PGS in non-humans was in fact a chromosomal diagnosis 
[5], by detecting the Barr Body in rabbit blastocysts. In a clinical setting, following the 
ultimately unsuccessful attempt to sex biopsy samples reliably using Y specific PCR 
[6], the group of Joy Delhanty introduced fluorescent in-situ hybridisation (FISH) for 
the sex chromosomes in preimplantation embryos using X and Y chromosome 
specific probes [51]. This was followed in 1992 by simultaneous detection of these 
chromosomes for the application of sexing human preimplantation embryonic nuclei 
[52-54] and between 1992 and 1994, twenty-seven treatment cycles were completed 
using this technique that resulted in nine pregnancies and five female live births [53-
55]. FISH was subsequently applied to aneuploidy screening and mosaicism 
detection in human preimplantation embryos, chiefly by Munné and colleagues [49, 
56-58] and this method for PGS was the most popular approach for the following 15 
years. It was applied for patients with indications of advanced maternal age, 
recurrent miscarriage and recurrent implantation failure. The technique (Figure 1) 
used a non-targeted approach, initially screening for e.g. chromosomes 13, 16, 18, 
21, 22 (X and Y) [49, 56-58]. However, this technology was the subject of 
controversy in the field [59], with retrospective analysis suggesting benefits in some 
clinics but randomized trial data suggesting that there was no demonstrable clinical 








































































































































































































(normal) DNA, that are competitively hybridized to metaphase chromosomes [73]. 
The signal intensity of the test DNA is then measured against that of the reference 
for each chromosome using computer software, thereby permitting the identification 
of copy number abnormalities [74]. This technology was initially used in 1992 to 
detect copy number changes in solid tumours and was at the forefront of cancer 
genetics research [75, 76]. Unlike other traditional techniques such as FISH, CGH 
allowed for the more rapid assessment of chromosome copy number in the entire 
genome [77]. However, one of the main limiting factors of this technology was the 
resolution, which was is limited to approximately 5-10Mb in most clinical applications 
[74, 78].  
Array comparative genomic hybridisation (aCGH) is a means of aneuploidy 
screening across the whole karyotype and involves WGA of biopsied cells followed 
by fluorescent labelling of both a test DNA sample (green) and a reference (normal) 
DNA sample (red) [79]. These samples are then allowed to hybridize to a tiling path 
microarray and the colour ratio is determined in order to identify whole or segmental 
chromosome copy number differences within the test sample. Therefore, aCGH 
allows for aneuploidy screening as well as identification of deletions and duplications 
of specific chromosomal regions [80-83]. In parallel to the development of aCGH, a 
general shift in preference for the timing of biopsy from the cleavage to the 
trophectoderm stage (and less commonly to the polar body stage) has largely 
brought about a renaissance in PGS, however the technology cannot detect a loss or 
gain of an entire set of chromosomes (e.g. triploidy). A study by Munné and 
colleagues determined that around 1.8% of embryos (n=91) were homogenously 
polyploid with no other detectable abnormalities [84-86]. Furthermore, the problem of 
chromosomal mosaicism (where embryos have populations of normal and abnormal 
cells) remains. Given the complexities of mosaicism however it is beyond the scope 
of this review to discuss in detail. 
An alternative method for detecting chromosome copy number was developed and 
validated by Treff and colleagues using real-time quantitative PCR (RT-qPCR) [87-
89]. RT-qPCR entails a pre-amplification step, followed by a high-order multiplex 
PCR reaction to amplify two regions on each arm of all the chromosomes. Rapid 
quantification of each product using RT-qPCR then allows for the evaluation of copy 
number over the whole genome [36]. One unique feature of this technology is that 
the PCR is performed directly on the sample, without any whole genome 
amplification (WGA) step first unlike other technologies such as aCGH and SNP 
microarrays (see below); minimising the risk of misdiagnosis through artefacts known 
to be introduced by WGA technology [90]. However, it is important to note that due to 
this, RT-qPCR can only be used on trophectoderm samples, meaning that sufficient 
blastocyst embryos need to be available [36, 89]. 
The availability of benchtop sequencing technology allowed for the development of 
next generation sequencing (NGS) technology for chromosome screening. This 
technique involves fragmentation of the whole genome amplified DNA into small 
pieces (100–200 base pairs). These fragments are then sequenced using 
fluorescent signals to indicate the relevant sample, an approach that can be 
achieved at very low cost. This occurs until a sufficient sequencing depth has been 
achieved [91]. The sequence data across the genome are compared with a 
reference genome and then counted with the use of specialist software [91]. The 
number of sequences from a specific chromosome is proportional to chromosome 
copy number, therefore trisomy or monosomy will result in greater or lower numbers 
of reads, respectively [90, 92]. This allows for both whole chromosome aneuploidy 
and segmental imbalances to be detected [93], has a greater dynamic range than 






























































































































AB (heterozygous) and the raw data from these provide the basis of karyomapping 
analysis.  
Almost 40 million SNPs have been validated that reside mostly in non-coding 
regions, with arrays generally detecting 660,000 to 2 million SNPs across the length 
of all chromosomes [36]. Due to the biallelic nature of SNPs, it is suggested that, on 
their own, they are less informative than STR markers [23]. However, by determining 
the genotype of the parents, and a relative of known disease status, four distinct sets 
of markers can be identified across each of the parental chromosomes [23]. A study 
by Rabinowitz et al., using SNP array technology, showed a 79% chemical 
pregnancy rate after screening for single gene defects [96]. Treff and colleagues 
applied this technology for PGD of unbalanced inheritance of rearranged 
chromosomes and aneuploidy screening of 12 patients, with a 75% birth rate [97] 
showing that SNP arrays may be particularly suited to PGD for monogenic disorders 
or translocation chromosome imbalance combined with comprehensive detection of 
aneuploidy [36]. Karyomapping however combines all these advantages of SNP 
arrays to create a single, widely applicable approach to preimplantation genetics. 
 
2. What is Karyomapping? 
Karyomapping [98] allows the determination of inheritance from the parental (or 
grandparental) genetic material through the assembly of haploblocks (inherited 
chromosomal segments). The approach involves genome-wide SNP analysis of 
parental DNA, amplified embryo DNA and an appropriate ‘reference’ such as a close 
relative (e.g. older child affected by the disorder). 
The first step is the identification of ‘informative’ loci for each of the parental 
haplotypes [99] at which one parent is homozygous and another heterozygous. All 
other loci are then disregarded as uninformative. These then need to be compared to 
the reference individual of known disease status in order to establish phase (i.e. 
assign a reference “affected” haplotype). At this stage, the genotype (SNP chip 
output) of each embryo within the cohort needs to be compared to the reference 
genotype to determine similarity at each informative locus. The resulting output 
(Figure 3- 4) creates a karyomap showing homologous chromosomes and 
crossovers. Comparison of the SNP markers present on the parental chromosomes 
at the chromosomal position of the gene(s) of interest with the reference genome 
against those present in the cells taken from the embryo allows the determination of 
the presence or absence of the mutant allele(s) by linkage [23] rather than direct 
mutation detection. Karyomapping can further be used for the diagnosis of 
aneuploidy (monosomy and meiotic trisomy (Figure 5)) triploidy, parthenogenetic 
activation and uniparental heterodisomy (which can lead to imprinting disorders such 
as Prader–Willi or Angelman syndromes), as well as abnormal patterns of genome 
duplication seen with, for example, molar pregnancies [98-100]. Specifically, 
karyomapping identifies monosomies and deletions by the absence of either 
haplotype from that parent and trisomies of meiotic origin only through the presence 
of both haplotypes from one parent in one or more sections of the chromosome [98]. 
One crucial advantage of karyomapping is that it allows for determination of 
heterozygous SNP calls, referred to as “key SNPs” which allows the risks associated 
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4. More detailed view of the three embryos above compare
 

































































































































































that affects the connective tissue to varying degrees [24]. This study determined that 
both methods for PGD differentiated between affected and unaffected embryos with 
high efficiency and accuracy (after cleavage stage biopsy). However, karyomapping 
was much more time efficient process due to the shortened pre-test work up 
requirement [24]. In a subsequent study the analysis compared karyomapping with 
direct mutation detection in 218 embryo samples from 44 clinical cycles. The study 
determined that karyomapping was concordant with direct mutation testing in 
213/218 (97.7%) cycles. Furthermore, the non-concordant samples were all in 
consanguineous regions [99, 100]. Giménez et al. looked at the use of karyomapping 
for a de novo deletion in the TSC2 gene, which is responsible for tuberous sclerosis 
[101]. An attempt at conventional PGD was completed; assessing a total of 26 SNP 
within the deleted region, the protocol developed was still insufficient for the 
conclusive diagnosis of all potential embryos produced by the couple. However, it 
was determined that karyomapping was able to detect the mutation. The patients 
underwent a PGD cycle using karyomapping which resulted in a healthy live-born 
child [101]. This study therefore confirmed that karyomapping is a powerful and 
versatile new approach for mutation detection in preimplantation embryos, some of 
which may be not be possible through conventional PGD methods. 
Furthermore, karyomapping is platform independent (though to date we believe only 
used with Illumina chips) as the output is binary [99], this allows any platform, not 
just SNP chips, to be used including whole-genome sequencing [101]. It is 
suggested that a whole genome sequence (a basic interrogation so that it takes a 
shorter time to generate) followed by karyomapping would allow an accurate, but 
rapid diagnosis [99]. However, it is important to note that even with the major 
developments in whole genome amplification; gaps would inevitably arise in the 
assembly. It is suggested that karyomapping could combat this by adaptations to the 
algorithm showing that the technology can evolve [101]. Karyomapping, therefore, is 
seen to have inherent ‘future-proofing’ and thus has the potential to form the 
foundation for most PGD worldwide [99]. Furthermore, it has been shown that 
karyomap analysis can be extended to include allele-specific intensity data, which 
allows sequence-identical chromosome duplications to be detected [102, 103]. It has 
also been demonstrated that adaptations of karyomapping can be used to assess 
post-zygotic copy number in embryos allowing the origin of trisomies to be 
differentiated [101]. This is an important advantage as mosaic trisomies of meiotic 
origin invariably lead to clinical problems however those of post-zygotic origin can, in 
certain circumstances, proceed uneventfully to term. The issue of PGS for 
chromosomal abnormalities remains controversial, however mounting data have 
provided evidence that it can be used to reduce the risk of miscarriage and disorders 
such as Down Syndrome [101, 104-107]. From a patient care perspective, the 
additional information relating to parental origin of meiotic errors provided by 
karyomapping (but not other PGD technologies) can help couples to determine 
which treatment option to try next, such as donor gametes [24]. 
It is important to note that significant savings can be made in labour as 
karyomapping does not require the in-depth workup required for customised tests as 
when performing multiplexed STR analysis. With this in mind, the per-sample cost 
for karyomapping is comparable to or less than the cost of traditional PGD 
technologies, depending on the complexity of the analysis [99, 100].  
 
2.1 Simultaneous detection of monogenic disorders and chromosome copy number: 
Alternatives to karyomapping 
There are other techniques that allow for the simultaneous detection of monogenic 
disorders and chromosome copy number in IVF derived human embryos. 
Haplarithmisis [103, 108] is one such method, which allows B allele frequencies to 
be called as well as the standard AA, BB or AB alleles we expect from SNP data. 
Zamani et al. argue that the process of whole-genome amplification is in itself 
problematic due to artefacts and thus other haplotyping methods suffer from error-
prone SNP genotypes (AA, AB, BB) and the relatively subjective nature of 
discriminating chromosome copy number changes from these artefacts [103, 108]. 
They suggest that Haplarithmisis could be used to diagnose specific disease causing 
alleles throughout the genome, as well as indicating the presence of numerical and 
structural chromosomal abnormalities in the embryos. Furthermore, it has been 
shown that using this technique, meiotic segregation errors can be distinguished 
from mitotic ones [108]. 
Treff et al. developed the use of RT-qPCR, demonstrating a targeted NGS strategy 
and a multiplex PCR reaction that included the chromosome-specific target 
sequences along with the mutation site [88]. This strategy reduced the necessary 
read depth for accurate sequencing of the mutation site as well as parallel RT-qPCR 
for chromosome copy number, which allows for a reduction in per sample cost as 
well as the time required to run the test [36]. Zimmerman and colleagues determined 
that this strategy was more reliable than other techniques [109] with 303/304 (99.7%) 
embryos getting a definitive diagnosis and 1/304 (0.3%) recorded as inconclusive 
due to a recombination event. This study also demonstrated an 82% (27/33) 
pregnancy rate [109]. 
Another interesting method is the use of NGS technology with linkage analysis. Yan 
and colleagues describe a technique called “mutated allele revealed by sequencing 
with aneuploidy and linkage analyses” (MARSALA) [110]. This method involves 
multiple annealing and looping-based amplification cycles (MALBAC) for whole-
genome amplification and subsequently, aneuploidy is determined by CNVs, 
whereas SNVs associated with the monogenic diseases are detected by PCR 
amplification of the MALBAC product. Aneuploidy is then detected by copy number 
variations (CNVs) and then detection of single-nucleotide variations (SNVs) in the 
PCR amplified MALBAC product determines the disease status of the sample. The 
false-positive and false-negative SNVs are avoided by an NGS based linkage 
analysis [110]. Furthermore, the study demonstrated that by using this method two 
viable and healthy live births were achieved [110]. 
 
2.2 Limitations of karyomapping 
It is important however to note that karyomapping also has a number of limitations. 
The need for DNA from a close relative of known disease status can limit the use of 
karyomapping, especially in cases where the disorder leads to shortened life 
expectancy. However, this is a limitation of the premise of PGD for single gene 
disorders in which linkage analysis is involved, not specific to the karyomapping 
technology itself. Secondly, if a recombination event in either parent, reference 
individual or embryo is next to the position of interest this may make the data difficult 
interpret and thus a diagnosis inconclusive. Regarding de novo mutations, it may not 
be possible with karyomapping to establish which parental chromosome is linked to 
the defect therefore, mutation testing is essential in these cases. As with all PGD 
technology therefore, karyomapping does not a-priori detect new mutations [111]. 
However, karyomapping can still be used to identify the affected parental 
chromosome in single sperm or embryo samples [23]. One other area of 
development for this technology, as is the same with all PGD technologies based on 
linkage analysis, is in cycles dealing with consanguinity. In these cases, the pattern 
of key and non-key SNPs identifies regions in which the parents and possibly the 
close relative share one or more sequence-identical chromosome regions. It is 
suggested that as these regions are less informative combined karyomapping and 
mutation detection would be the most appropriate course of action [23, 99]. Another 
issue with karyomapping, already alluded to, is the fact that it cannot easily detect 
trisomies of post-zygotic origin unless combined with quantitative approaches. 
From a practical standpoint, it is important to note is that there are cost implications 
regarding the implementation of karyomapping. If the lab follows the published 
Illumina protocol, karyomapping requires 4 products: SureMDA™, DNA Analysis Kit, 
the iScan® System or NextSeq® 550 System, and BlueFuse® Multi analysis 
software [112]. The scanning system required to read the BeadChips are different for 
those required for NGS (VeriSeq®), and further to this karyomapping requires MDA 
to amplify the DNA instead of WGA commonly used in aCGH and NGS. Due to 
these requirements, there is also a need for dedicated workrooms for each stage of 
sample preparation that adds to the logistical costs of running a karyomapping 
assay.   
Although patient work up for karyomapping is acknowledged to be shorter than that 
of other methods for mutation detection, in the case of disorders that have not been 
mapped by classical PGD techniques, STR marker tests need to be developed 
before karyomapping can be performed. This then means that the work up time for 
karyomapping is the same other technologies.  
 
3. Expert Commentary 
Karyomapping was first commercialized by Illumina in 2013 and is currently a routine 
procedure for PGD detection of single gene disorders. At time of writing (November 
2016) around 1000 clinics worldwide offer karyomapping, with detection largely 
serviced by 20 diagnostic laboratories. Approximately 2500 cases have been 
performed, a figure almost certainly out of date by the time this article is being read 
[113]. Because of issues of inability to detect post-zygotic trisomy reliably however 
and the confounding problems of embryo mosaicism, karyomapping has yet to be 
applied clinically in a widespread manner for the detection of chromosome disorders. 
When this occurs then it will be able to reach its full potential as a method to 
simultaneously detect chromosomal abnormalities and monogenic disorders. 
 
4. Five Year View 
Over the next five years we predict that the use of karyomapping will increase. With 
its current widespread use for monogenic disorders this seems inevitable, and thus a 
range of manuscripts associated with its validation is very likely. Given its potential 
for chromosomal detection, validation for cytogenetic diagnoses is likely to follow, 
however the issue of detection of post-zygotic chromosome imbalance (which cannot 
be achieved by karyomapping alone) needs to be addressed. This will be achieved 
by combining karyomapping with quantitative SNP detection and this has already 
been applied to some degree in the Haplarithmisis algortihm [102]). For a test to 
become truly widespread it also need to be affordable and again it seems likely that 
the overall cost of the test will reduce as economies of scale become apparent. 
Given that NGS technologies are also becoming widespread for aneuploidy 
detection it would be refreshing to see the karyomapping algorithms adapted to use 
sequencing data rather than SNP chips. 
 
Key issues 
 Preimplantation genetic diagnosis and screening (PGD/PGS) has been 
applied clinically for >25 years however inherent drawbacks include the necessity to 
tailor each case to the trait in question 
 Technologies to detect monogenic and chromosomal disorders respectively 
are fundamentally different to one another 
 Adapting to changes in technology has been a challenge over the last 25 
years and there is constantly a need for more efficient, streamlined diagnoses.  
 Karyomapping allows the determination of inheritance from the 
(grand)parental haplobocks through assembly of inherited chromosomal segments. 
The output displays homologous chromosomes, crossovers and the genetic status of 
the embryos by linkage comparison, as well as chromosomal disorders.  
 Karyomapping also allows for determination of heterozygous SNP calls, 
avoiding the risks of allele dropout, a common problem with other PGD techniques.  
 Manuscripts documenting the evolution of preimplantation genetics, especially 
those investigating technologies that simultaneously detect monogenic and 
chromosomal disorders, are reviewed here. 
 Karyomapping is currently available for detection of single gene disorders; 
~1000 clinics worldwide offer it (via ~20 diagnostic laboratories) and ~2500 cases 
have been performed.  
 Due an inability to detect post-zygotic trisomy reliably however and 
confounding problems of embryo mosaicism, karyomapping has yet to be applied 
clinically for detection of chromosome disorders. 
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